LIDDS.ST
LIDDS AB (publ) [LIDDS.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LIDDS.ST Stock Summary
Top 10 Correlated ETFs
LIDDS.ST
Top 10 Correlated Stocks
LIDDS.ST
In the News
LIDDS.ST Financial details
Company Rating
Neutral
Market Cap
11.26M
Income
-40.26M
Revenue
0
Book val./share
0.2
Cash/share
0.2
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-0.7
Forward P/E
-
PEG
0.19
P/S
-216.24
P/B
0.66
P/C
0.82
P/FCF
-0.72
Quick Ratio
4.43
Current Ratio
4.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.63
EPS next Y
-
EPS next Q
-
EPS this Y
-37%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
306.63%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-85%
ROE
-96%
ROC
-0.93%
Gross Margin
100%
Oper. Margin
27598%
Profit Margin
28138%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.103-1.395
52W High
-
52W Low
-
RSI
47
Rel Volume
1.61
Avg Volume
161.63K
Volume
259.53K
Perf Week
-9.19%
Perf Month
3.16%
Perf Quarter
-10.19%
Perf Half Y
-18.5%
-
-
-
-
Beta
0.237
-
-
Volatility
0.01%, 0.02%
Prev Close
-0.61%
Price
0.163
Change
-3.83%
LIDDS.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0.1 | 0.05 | 0 | |
| Net income per share | -0.93 | -1.12 | -1.08 | -1 | -0.63 | |
| Operating cash flow per share | -0.67 | -0.95 | -1.24 | -0.96 | -0.41 | |
| Free cash flow per share | -1.41 | -1.08 | -1.31 | -0.98 | -0.42 | |
| Cash per share | 0.3 | 1.25 | 0.99 | 0.14 | 0.21 | |
| Book value per share | 5.96 | 1.48 | 1.41 | 0.41 | 0.22 | |
| Tangible book value per share | 0.15 | 0.97 | 0.94 | -0.04 | 0.22 | |
| Share holders equity per share | 5.96 | 1.48 | 1.41 | 0.41 | 0.22 | |
| Interest debt per share | 0 | 0 | 0 | 0.12 | 0 | |
| Market cap | 400.53M | 426.47M | 328.92M | 62.76M | 6.85M | |
| Enterprise value | 392.97M | 390.4M | 294.92M | 61.5M | -6.66M | |
| P/E ratio | -16.81 | -13.19 | -8.83 | -1.69 | -0.17 | |
| Price to sales ratio | 0 | 1.24K | 92.55 | 33.24 | 0 | |
| POCF ratio | -23.43 | -15.55 | -7.71 | -1.76 | -0.26 | |
| PFCF ratio | -11.12 | -13.68 | -7.3 | -1.72 | -0.26 | |
| P/B Ratio | 2.63 | 9.96 | 6.78 | 4.09 | 0.49 | |
| PTB ratio | 2.63 | 9.96 | 6.78 | 4.09 | 0.49 | |
| EV to sales | 0 | 1.13K | 82.98 | 32.57 | 0 | |
| Enterprise value over EBITDA | -22.06 | -12.26 | -8.01 | -1.7 | 0.27 | |
| EV to operating cash flow | -22.99 | -14.24 | -6.92 | -1.73 | 0.25 | |
| EV to free cash flow | -10.91 | -12.53 | -6.55 | -1.69 | 0.25 | |
| Earnings yield | -0.06 | -0.08 | -0.11 | -0.59 | -5.87 | |
| Free cash flow yield | -0.09 | -0.07 | -0.14 | -0.58 | -3.87 | |
| Debt to equity | 0 | 0 | 0 | 0.26 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0.15 | 0 | |
| Net debt to EBITDA | 0.42 | 1.13 | 0.92 | 0.04 | 0.54 | |
| Current ratio | 1.57 | 3.39 | 5.38 | 0.76 | 4.22 | |
| Interest coverage | -5.02K | -4.04K | 0 | -139.76 | -666.79 | |
| Income quality | 0.72 | 0.85 | 1.14 | 0.97 | 0.65 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 74.9 | 8.46 | 12.03 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.94 | 0.27 | 0.29 | 0.65 | 0 | |
| Capex to operating cash flow | 1.11 | 0.14 | 0.06 | 0.02 | 0.01 | |
| Capex to revenue | 0 | -10.86 | -0.68 | -0.43 | 0 | |
| Capex to depreciation | -3.15 | -7.68 | -5.18 | -1.68 | -0.02 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 11.2 | 6.1 | 5.86 | 3.06 | 1.77 | |
| ROIC | -0.16 | -0.76 | -0.77 | -1.91 | -2.93 | |
| Return on tangible assets | -2.46 | -0.82 | -0.95 | -4.1 | -2.28 | |
| Graham Net | 0.11 | 0.91 | 0.85 | -0.1 | 0.18 | |
| Working capital | 3.42M | 27.18M | 30.95M | -2.54M | 12.1M | |
| Tangible asset value | 3.73M | 28.15M | 32.26M | -1.51M | 13.9M | |
| Net current asset value | 3.42M | 27.18M | 30.95M | -2.54M | 12.1M | |
| Invested capital | 0 | 0 | 0 | 0.26 | 0 | |
| Average receivables | 750.61K | 1.75M | 2.48M | 2.46M | 1.91M | |
| Average payables | 3.1M | 4.77M | 4.2M | 1.9M | 1.47M | |
| Average inventory | 159.72K | 415.72K | 256K | -499.5 | -499.5 | |
| Days sales outstanding | 0 | 2.11K | 304.82 | 377.37 | 0 | |
| Days payables outstanding | 15.31K | 89.92 | 19.77 | 15.01 | 31.43 | |
| Days of inventory on hand | 1.46K | 7.44 | 0 | -0.01 | 0 | |
| Receivables turnover | 0 | 0.17 | 1.2 | 0.97 | 0 | |
| Payables turnover | 0.02 | 4.06 | 18.46 | 24.31 | 11.61 | |
| Inventory turnover | 0.25 | 49.09 | 0 | -38.55K | 0 | |
| ROE | -0.16 | -0.76 | -0.77 | -2.42 | -2.89 | |
| Capex per share | -0.74 | -0.13 | -0.07 | -0.02 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.25 | -0.18 | -0.11 | -0.07 | -0.27 | |
| Operating cash flow per share | -0.27 | -0.19 | -0.1 | -0.08 | -0.05 | |
| Free cash flow per share | -0.27 | -0.19 | -0.1 | -0.08 | -0.05 | |
| Cash per share | 0.14 | 0.56 | 0.33 | 0.25 | 0.2 | |
| Book value per share | 0.41 | 0.83 | 0.54 | 0.48 | 0.2 | |
| Tangible book value per share | -0.04 | 0.52 | 0.3 | 0.23 | 0.2 | |
| Share holders equity per share | 0.41 | 0.83 | 0.54 | 0.48 | 0.2 | |
| Interest debt per share | 0.11 | 0 | 0 | 0 | 0 | |
| Market cap | 63.39M | 77.57M | 33.02M | 18.29M | 7.37M | |
| Enterprise value | 62.13M | 47.75M | 10.32M | 1.19M | -6.14M | |
| P/E ratio | -1.69 | -2 | -1.12 | -1.01 | -0.1 | |
| Price to sales ratio | -576.29 | 0 | 0 | 0 | 0 | |
| POCF ratio | -6.23 | -7.66 | -4.68 | -3.3 | -2.11 | |
| PFCF ratio | -6.19 | -7.63 | -4.63 | -3.26 | -2.06 | |
| P/B Ratio | 4.13 | 1.74 | 0.89 | 0.56 | 0.53 | |
| PTB ratio | 4.13 | 1.74 | 0.89 | 0.56 | 0.53 | |
| EV to sales | -564.79 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -7.12 | -5.05 | -1.42 | -0.27 | 1.59 | |
| EV to operating cash flow | -6.1 | -4.72 | -1.46 | -0.22 | 1.76 | |
| EV to free cash flow | -6.06 | -4.69 | -1.45 | -0.21 | 1.71 | |
| Earnings yield | -0.15 | -0.12 | -0.22 | -0.25 | -2.53 | |
| Free cash flow yield | -0.16 | -0.13 | -0.22 | -0.31 | -0.49 | |
| Debt to equity | 0.26 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.15 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 0.14 | 3.15 | 3.13 | 3.88 | 3.5 | |
| Current ratio | 0.76 | 5.47 | 4.78 | 4.85 | 4.22 | |
| Interest coverage | -34.26 | -170.91 | -7.38K | -1.51K | -19.19K | |
| Income quality | 1.15 | 1.06 | 0.96 | 1.22 | 0.19 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -43.76 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.65 | 0.33 | 0.4 | 0.47 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0.01 | 0.01 | 0.02 | |
| Capex to revenue | 0.56 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.5 | -0.39 | -0.64 | -0.66 | -0.01 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.52 | 1.84 | 1.15 | 0.84 | 1.12 | |
| ROIC | -0.47 | -0.22 | -0.2 | -0.14 | -1.38 | |
| Return on tangible assets | -1.03 | -0.29 | -0.29 | -0.23 | -1.06 | |
| Graham Net | -0.11 | 0.46 | 0.26 | 0.21 | 0.16 | |
| Working capital | -2.54M | 26.66M | 19.32M | 14.83M | 12.1M | |
| Tangible asset value | -1.51M | 27.6M | 20.18M | 15.6M | 13.9M | |
| Net current asset value | -2.54M | 26.66M | 19.32M | 14.83M | 12.1M | |
| Invested capital | 0.26 | 0 | 0 | 0 | 0 | |
| Average receivables | 2.18M | 2.78M | 2.26M | 1.66M | 1.73M | |
| Average payables | 2.37M | 1.76M | 1.5M | 1.26M | 1.41M | |
| Average inventory | -45.5K | -2.28M | -2.26M | -864K | 0 | |
| Days sales outstanding | -2.27K | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 16.27 | 1.48K | 808.47 | 1.11K | 7.93 | |
| Days of inventory on hand | -18.17 | -2.12K | -1.32K | 0 | 0 | |
| Receivables turnover | -0.04 | 0 | 0 | 0 | 0 | |
| Payables turnover | 5.53 | 0.06 | 0.11 | 0.08 | 11.35 | |
| Inventory turnover | -4.95 | -0.04 | -0.07 | 0 | 0 | |
| ROE | -0.61 | -0.22 | -0.2 | -0.14 | -1.34 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
LIDDS.ST Frequently Asked Questions
What is LIDDS AB (publ) stock symbol ?
LIDDS AB (publ) is a SE stock and trading under the symbol LIDDS.ST
What is LIDDS AB (publ) stock quote today ?
LIDDS AB (publ) stock price is $0.163 today.
Is LIDDS AB (publ) stock public?
Yes, LIDDS AB (publ) is a publicly traded company.
Company Profile
- Volume Average 161.63K
- Market Capitalization 11.26M
- Employee 2
- CEO Ms. Jenni Bjornulfson
- Headquarters Uppsala,SE
- IPO Date 2014-07-31
-
Website
https://www.liddspharma.com 
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations. The company is based in Uppsala, Sweden.
